AMERGE
LOE ApproachingNDAORALTABLET
Approved
Feb 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMERGE is an oral small-molecule tablet approved in 1998 for migraine treatment. The specific mechanism of action and therapeutic indications are not disclosed in available data. This is a mature branded product currently approaching loss of exclusivity.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) signals transition planning and potential team consolidation in the coming 12–24 months.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Special Drug Use Investigation for AMERGE® Tablet (Long-term)
Started May 2009
300 enrolled
Migraine Disorders
Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet
Started Apr 2009
500 enrolled
Migraine Disorders
Career Relevance
Zero linked job postings indicate this is not a growth priority for GSK recruitment. Working on AMERGE offers limited career momentum; roles are focused on maintaining market share and managing decline rather than innovation or expansion. Consider this assignment a stabilization role or stepping stone to higher-growth GSK assets.
Brand Manager
Worked on AMERGE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.